Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells

Cell Cycle

Volumn 11, Issue 24, 2012, Pages 4597-4612

  Baldwin, R Mitchell ^a   Morettin, Alan ^a   Paris, Genevieve ^a   Goulet, Isabelle ^a   Cot̂é, Jocelyn ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Apoptosis; Breast cancer; Invasion; Motility; Protein arginine methyltransferase; catenin

Indexed keywords

BETA CATENIN; PROTEIN ARGININE METHYLTRANSFERASE; RNA;

APOPTOSIS; ARTICLE; BIOCHEMISTRY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL ADHESION; CELL INVASION; CELL STRUCTURE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; RNA INTERFERENCE;

EID: 84871496525     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22871     Document Type: Article

References (78)

1. Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. Mol Cell 2009; 33:1-13; PMID:19150423; http://dx.doi.org/10.1016/ j.molcel.2008.12.013.
2. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 1999; 9:207-10; PMID:10074433; http://dx.doi.org/10.1016/S0960-9822(99)80091-8.
3. Zurita-Lopez CI, Sandberg T, Kelly R, Clarke SG. Human Protein Arginine Methyltransferase 7 (PRMT7) is a Type III Enzyme Forming omega-NG-Monomethylated Arginine Residues. J Biol Chem 2012; 287:29801-14; PMID:22761421; http://dx.doi.org/10.1074/jbc.M111.336271.
4. Boisvert FM, Chénard CA, Richard S. Protein interfaces in signaling regulated by arginine methylation. Sci STKE 2005; 2005:re2; PMID:15713950; http://dx.doi.org/10.1126/stke.2712005re2.
5. Ong SE, Mittler G, Mann M. Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. Nat Methods 2004; 1:119-26; PMID:15782174; http://dx.doi.org/10.1038/nmeth715.
6. Boisvert FM, Côté J, Boulanger MC, Richard S. A proteomic analysis of arginine-methylated protein complexes. Mol Cell Proteomics 2003; 2:1319-30; PMID:14534352; http://dx.doi.org/10.1074/mcp.M300088-MCP200.
7. Goulet I, Gauvin G, Boisvenue S, Côté J. Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization. J Biol Chem 2007; 282:33009-21; PMID:17848568; http://dx.doi.org/10.1074/jbc.M704349200.
8. Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, et al. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 2004; 101:83-9; PMID:15221992; http://dx.doi.org/10.1002/cncr.20327.
9. Mathioudaki K, Scorilas A, Ardavanis A, Lymberi P, Tsiambas E, Devetzi M, et al. Clinical evaluation of PRMT1 gene expression in breast cancer. Tumour Biol 2011; 32:575-82; PMID:21229402; http://dx.doi.org/10.1007/s13277-010-0153- 2.
10. Cheung N, Chan LC, Thompson A, Cleary ML, So CW. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 2007; 9:1208-15; PMID:17891136; http://dx.doi.org/10.1038/ncb1642.
11. Kim YR, Lee BK, Park RY, Nguyen NT, Bae JA, Kwon DD, et al. Differential CARM1 expression in prostate and colorectal cancers. BMC Cancer 2010; 10:197; PMID:20462455; http://dx.doi.org/10.1186/1471-2407-10-197.
12. Mathioudaki K, Papadokostopoulou A, Scorilas A, Xynopoulos D, Agnanti N, Talieri M. The PRMT1 gene expression pattern in colon cancer. Br J Cancer 2008; 99:2094-9; PMID:19078953; http://dx.doi.org/10.1038/sj.bjc.6604807.
13. Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 2011; 128:562-73; PMID:20473859; http://dx.doi.org/10.1002/ijc.25366.
14. Pal S, Baiocchi RA, Byrd JC, Grever MR, Jacob ST, Sif S. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J 2007; 26:3558-69; PMID:17627275; http://dx.doi.org/10.1038/sj. emboj.7601794.
15. Papadokostopoulou A, Mathioudaki K, Scorilas A, Xynopoulos D, Ardavanis A, Kouroumalis E, et al. Colon cancer and protein arginine methyltransferase 1 gene expression. Anticancer Res 2009; 29:1361-6; PMID:19414388.
16. Frietze S, Lupien M, Silver PA, Brown M. CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Res 2008; 68:301-6; PMID:18172323; http://dx.doi.org/10.1158/0008-5472.CAN-07- 1983.
17. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 2004; 24:9630-45; PMID:15485929; http://dx.doi.org/10.1128/MCB.24.21.9630-9645.2004.
18. Vezzalini M, Aletta JM, Beghelli S, Moratti E, Della Peruta M, Mafficini A, et al. Immunohistochemical detection of arginine methylated proteins (MeRP) in archival tissues. Histopathology 2010; 57:725-33; PMID:21083602; http://dx.doi.org/10.1111/j.1365-2559.2010.03684.x.
19. Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghou K, et al. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell 2008; 31:212-21; PMID:18657504; http://dx.doi.org/10.1016/j.molcel.2008.05.025.
20. Côté J, Boisvert FM, Boulanger MC, Bedford MT, Richard S. Sam68 RNA binding protein is an in vivo substrate for protein arginine N-methyltransferase 1. Mol Biol Cell 2003; 14:274-87; PMID:12529443; http://dx.doi.org/10.1091/mbc.E02-08-0484.
21. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184:39-51; PMID:7622868; http://dx.doi.org/10.1016/0022-1759(95)00072-I.
22. Mooney LM, Al-Sakkaf KA, Brown BL, Dobson PR. Apoptotic mechanisms in T47D and MCF-7 human breast cancer cells. Br J Cancer 2002; 87:909-17; PMID:12373608; http://dx.doi.org/10.1038/sj.bjc.6600541.
23. Walsh JG, Cullen SP, Sheridan C, Lüthi AU, Gerner C, Martin SJ. Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci USA 2008; 105:12815-9; PMID:18723680; http://dx.doi.org/10.1073/ pnas.0707715105.
24. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004; 83:249-89; PMID:14758095; http://dx.doi.org/10.1023/B:BREA.0000014042.54925.cc.
25. Herrmann F, Pably P, Eckerich C, Bedford MT, Fackelmayer FO. Human protein arginine methyltransferases in vivo--distinct properties of eight canonical members of the PRMT family. J Cell Sci 2009; 122:667-77; PMID:19208762; http://dx.doi.org/10.1242/jcs.039933.
26. Herrmann F, Fackelmayer FO. Nucleo-cytoplasmic shuttling of protein arginine methyltransferase 1 (PRMT1) requires enzymatic activity. Genes Cells 2009; 14:309-17; PMID:19170758; http://dx.doi.org/10.1111/j.1365-2443.2008. 01266.x.
27. Wada K, Inoue K, Hagiwara M. Identification of methylated proteins by protein arginine N-methyltransferase 1, PRMT1, with a new expression cloning strategy. Biochim Biophys Acta 2002; 1591:1-10; PMID:12183049; http://dx.doi.org/10.1016/S0167-4889(02)00202-1.
28. Liu X, Feng R. Inhibition of epithelial to mesenchymal transition in metastatic breast carcinoma cells by c-Src suppression. Acta Biochim Biophys Sin (Shanghai) 2010; 42:496-501; PMID:20705589; http://dx.doi.org/10.1093/abbs/ gmq043.
29. Shtutman M, Levina E, Ohouo P, Baig M, Roninson IB. Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res 2006; 66:11370-80; PMID:17145883; http://dx.doi.org/10.1158/0008-5472.CAN-06-2106.
30. Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans 2005; 33:891-5; PMID:16246005; http://dx.doi.org/10.1042/BST20050891.
31. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005; 21:247-69; PMID:16212495; http://dx.doi.org/10.1146/annurev. cellbio.21.020604.150721.
32. Schafer DA. Cell biology: barbed ends rule. Nature 2004; 430:734-5; PMID:15306794; http://dx.doi.org/10.1038/430734a.
33. Tomaskovic-Crook E, Thompson EW, Thiery JP. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 2009; 11:213; PMID:19909494; http://dx.doi.org/10.1186/bcr2416.
34. Jourquin J, Yang N, Kam Y, Guess C, Quaranta V. Dispersal of epithelial cancer cell colonies by lysophosphatidic acid (LPA). J Cell Physiol 2006; 206:337-46; PMID:16110477; http://dx.doi.org/10.1002/jcp.20470.
35. de Rooij J, Kerstens A, Danuser G, Schwartz MA, Waterman-Storer CM. Integrin-dependent actomyosin contraction regulates epithelial cell scattering. J Cell Biol 2005; 171:153-64; PMID:16216928; http://dx.doi.org/10.1083/jcb. 200506152.
36. Machesky LM. Lamellipodia and filopodia in metastasis and invasion. FEBS Lett 2008; 582:2102-11; PMID:18396168; http://dx.doi.org/10.1016/j.febslet.2008. 03.039.
37. Thiery JP, Chopin D. Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 1999; 18:31-42; PMID:10505544; http://dx.doi.org/10.1023/A:1006256219004.
38. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 2006; 118:290-301; PMID:16080193; http://dx.doi.org/10.1002/ijc.21355.
39. Yao H, Ashihara E, Maekawa T. Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets 2011; 15:873-87; PMID:21486121; http://dx.doi.org/10.1517/14728222.2011.577418.
40. Van Aken E, De Wever O, Correia da Rocha AS, Mareel M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch 2001; 439:725-51; PMID:11787845.
41. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993; 9:317-21; PMID:8236461; http://dx.doi.org/10.1016/0168-9525(93)90250-L.
42. Latres E, Chiaur DS, Pagano M. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 1999; 18:849-54; PMID:10023660; http://dx.doi.org/10. 1038/sj.onc.1202653.
43. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 1999; 13:270-83; PMID:9990852; http://dx.doi.org/10.1101/gad.13.3.270.
44. Scorilas A, Black MH, Talieri M, Diamandis EP. Genomic organization, physical mapping, and expression analysis of the human protein arginine methyltransferase 1 gene. Biochem Biophys Res Commun 2000; 278:349-59; PMID:11097842; http://dx.doi.org/10.1006/bbrc.2000.3807.
45. Scott HS, Antonarakis SE, Lalioti MD, Rossier C, Silver PA, Henry MF. Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2). Genomics 1998; 48:330-40; PMID:9545638; http://dx.doi.org/10.1006/geno.1997.5190.
46. Yu Z, Chen T, Hébert J, Li E, Richard S. A mouse PRMT1 null allele defines an essential role for arginine methylation in genome maintenance and cell proliferation. Mol Cell Biol 2009; 29:2982-96; PMID:19289494; http://dx.doi.org/10.1128/MCB.00042-09.
47. An W, Kim J, Roeder RG. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 2004; 117:735-48; PMID:15186775; http://dx.doi.org/10.1016/j.cell.2004.05.009.
48. Boisvert FM, Déry U, Masson JY, Richard S. Arginine methylation of MRE11 by PRMT1 is required for DNA damage checkpoint control. Genes Dev 2005; 19:671-6; PMID:15741314; http://dx.doi.org/10.1101/gad.1279805.
49. Boisvert FM, Rhie A, Richard S, Doherty AJ. The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary for 53BP1 DNA binding activity. Cell Cycle 2005; 4:1834-41; PMID:16294045; http://dx.doi.org/10.4161/cc.4.12. 2250.
50. Yu Z, Vogel G, Coulombe Y, Dubeau D, Spehalski E, Hébert J, et al. The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation. Cell Res 2012; 22:305-20; PMID:21826105; http://dx.doi.org/10.1038/ cr.2011.128.
51. Mitchell TR, Glenfield K, Jeyanthan K, Zhu XD. Arginine methylation regulates telomere length and stability. Mol Cell Biol 2009; 29:4918-34; PMID:19596784; http://dx.doi.org/10.1128/MCB.00009-09.
52. Cho JH, Lee MK, Yoon KW, Lee J, Cho SG, Choi EJ. Arginine methylation-dependent regulation of ASK1 signaling by PRMT1. Cell Death Differ 2012; 19:859-70; PMID:22095282; http://dx.doi.org/10.1038/cdd.2011.168.
53. Sakamaki J, Daitoku H, Ueno K, Hagiwara A, Yamagata K, Fukamizu A. Arginine methylation of BCL-2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt. Proc Natl Acad Sci USA 2011; 108:6085-90; PMID:21444773; http://dx.doi.org/10.1073/pnas.1015328108.
54. Robin-Lespinasse Y, Sentis S, Kolytcheff C, Rostan MC, Corbo L, Le Romancer M. hCAF1, a new regulator of PRMT1-dependent arginine methylation. J Cell Sci 2007; 120:638-47; PMID:17264152; http://dx.doi.org/10.1242/jcs.03357.
55. Berthet C, Guéhenneux F, Revol V, Samarut C, Lukaszewicz A, Dehay C, et al. Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. Genes Cells 2002; 7:29-39; PMID:11856371; http://dx.doi.org/10.1046/j.1356-9597.2001.00497.x.
56. Zhang X, Cheng X. Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure 2003; 11:509-20; PMID:12737817; http://dx.doi.org/10.1016/S0969- 2126(03)00071-6.
57. Yonemura S. Cadherin-actin interactions at adherens junctions. Curr Opin Cell Biol 2011; 23:515-22; PMID:21807490; http://dx.doi.org/10.1016/j.ceb.2011. 07.001.
58. Morrogh M, Andrade VP, Giri D, Sakr RA, Paik W, Qin LX, et al. Cadherin-catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Res Treat 2012; 132:641-52; PMID:22080244; http://dx.doi.org/10.1007/ s10549-011-1860-0.
59. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994; 1198:11-26; PMID:8199193.
60. Faleiro-Rodrigues C, Macedo-Pinto IM, Maia SS, Vieira RH, Lopes CS. Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumours. Gynecol Obstet Invest 2005; 60:75-83; PMID:15785075; http://dx.doi.org/10.1159/000084614.
61. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS. Loss of beta-catenin is associated with poor survival in ovarian carcinomas. Int J Gynecol Pathol 2004; 23:337-46; PMID:15381903; http://dx.doi.org/10.1097/01.pgp. 0000139711.22158.14.
62. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006; 66:5487-94; PMID:16707478; http://dx.doi.org/10.1158/0008-5472.CAN-06-0100.
63. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997; 183:404-11; PMID:9496256; http://dx.doi.org/10.1002/(SICI)1096-9896(199712)183:4〈404:: AIDPATH1148〉3.0.CO;2-9.
64. Yoshida R, Kimura N, Harada Y, Ohuchi N. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 2001; 18:513-20; PMID:11179480.
65. Nakopoulou L, Mylona E, Papadaki I, Kavantzas N, Giannopoulou I, Markaki S, et al. Study of phos-pho- beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod Pathol 2006; 19:556-63; PMID:16474376; http://dx.doi.org/10.1038/modpathol. 3800562.
66. Pontes J Jr., Srougi M, Borra PM, Dall' Oglio MF, Ribeiro-Filho LA, Leite KR. E-cadherin and betacatenin loss of expression related to bone metastasis in prostate cancer. Appl Immunohistochem Mol Morphol 2010; 18:179-84; PMID:18685493; http://dx.doi.org/10.1097/PAI.0b013e3181640bca.
67. Ebert MP, Yu J, Hoffmann J, Rocco A, Röcken C, Kahmann S, et al. Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol 2003; 21:1708-14; PMID:12721245; http://dx.doi.org/10.1200/JCO.2003.10.017.
68. Cha B, Kim W, Kim YK, Hwang BN, Park SY, Yoon JW, et al. Methylation by protein arginine methyltransferase 1 increases stability of Axin, a negative regulator of Wnt signaling. Oncogene 2011; 30:2379-89; PMID:21242974; http://dx.doi.org/10.1038/onc.2010.610.
69. Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 2011; 16:404-14; PMID:21406469; http://dx.doi.org/10.1634/theoncologist.2010-0402.
70. Navarro-Tito N, Robledo T, Salazar EP. Arachidonic acid promotes FAK activation and migration in MDA-MB-231 breast cancer cells. Exp Cell Res 2008; 314:3340-55; PMID:18804105; http://dx.doi.org/10.1016/j.yexcr.2008.08.018.
71. Zheng S, Huang J, Zhou K, Zhang C, Xiang Q, Tan Z, et al. 17β-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin. PLoS One 2011; 6:e22439; PMID:21818323; http://dx.doi.org/10.1371/journal.pone.0022439.
72. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170:1445-53; PMID:17456751; http://dx.doi.org/ 10.2353/ajpath.2007.070011.
73. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget 2011; 2:833-49; PMID:22064833.
74. Hwang CI, Choi J, Zhou Z, Flesken-Nikitin A, Tarakhovsky A, Nikitin AY. MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF. Cell Cycle 2011; 10:3834-40; PMID:22071625; http://dx.doi.org/10.4161/cc.10.22.18294.
75. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137:87-98; PMID:19345189; http://dx.doi.org/10.1016/j.cell.2009.01.039.
76. Baldwin RM, Garratt-Lalonde M, Parolin DA, Krzyzanowski PM, Andrade MA, Lorimer IA. Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling. Oncogene 2006; 25:2909-19; PMID:16331246; http://dx.doi.org/10.1038/sj.onc.1209312.
77. Hubers L, Valderrama-Carvajal H, Laframboise J, Timbers J, Sanchez G, Côté J. HuD interacts with survival motor neuron protein and can rescue spinal muscular atrophy-like neuronal defects. Hum Mol Genet 2011; 20:553-79; PMID:21088113; http://dx.doi.org/10.1093/hmg/ddq500.
78. Sang RL, Johnson JF, Taves J, Nguyen C, Wallert MA, Provost JJ. alpha(1)-Adrenergic receptor stimulation of cell motility requires phospholipase D-mediated extracellular signal-regulated kinase activation. Chem Biol Drug Des 2007; 69:240-50; PMID:17461971; http://dx.doi.org/10.1111/j.1747-0285.2007. 00502.x.